Investigational drug · Phase 2
LYT-200
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Cancer, Solid Tumor, Head and Neck Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "LYT-200"
First trial start
2020
Dec 11, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LYT-200", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Cancer
- Solid Tumor
- Head and Neck Cancer
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "LYT-200" as an intervention, largest first.
PureTechIndustry
NCT05829226 · 101 participants · Start Dec 12, 2022 · Primary completion Dec 31, 2025
Drug: LYT-200; Venetoclax and 2 more · For: AML, Adult Recurrent; MDS
Sites: Los Angeles, California; Orange, California; Miami, Florida · 9 sites in all
PureTechIndustry
NCT04666688 · 44 participants · Start Dec 11, 2020 · Primary completion Dec 12, 2024
Drug: LYT-200; Tislelizumab · For: Metastatic Cancer; Solid Tumor; Head and Neck Cancer
Sites: Los Angeles, California; Denver, Colorado; Sarasota, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation.
Huang X, Zhang S, Li J, et al. · Biochim Biophys Acta Rev Cancer 2025
- Chimera and Tandem-Repeat Type Galectins: The New Targets for Cancer Immunotherapy.
Ko FCF, Yan S, Lee KW, et al. · Biomolecules 2023
Also in development for Metastatic Cancer
- LY188011Phase 22 trials
Eli Lilly · Neoplasms, Child, Adolescent
- ART0380Phase 21 trial
Artios Pharma Ltd · Advanced Cancer, Metastatic Cancer, Ovarian Cancer
- AU-007Phase 21 trial
Aulos Bioscience, Inc. · Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma
- CJRB-101Phase 21 trial
CJ Bioscience, Inc. · NSCLC, HNSCC, Melanoma
- EvalstotugBA3071Phase 21 trial
BioAtla, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- INX-315Phase 21 trial
Incyclix Bio · Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor
- MerestinibLY2801653Phase 21 trial
Eli Lilly · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.